Director John Christopher “J.C.” Rozendaal was mentioned as representing Teva Pharmaceuticals in the article "How Will the Federal Circuit Replace Judge O'Malley? Plus: AI Can Be an Inventor--in the Southern Hemisphere," published by Law.com. From the article:
"Sterne Kessler Goldstein & Fox director J.C. Rozendaal will argue for Teva that Narcan is 'a well-known drug with well-known excipients being used a well-known manner.' The obstacle to creating Narcan wasn’t technical, it was commercial, Rozendaal argues in briefs. The patent on naloxone expired decades ago, meaning that expected profits could not support obtaining FDA approval. 'But support from FDA helped change all that in 2012.' That, he says, was the motivation to combine."